-
Improved In Vitro Evaluation of Drug Responses in Cancer Res
2026-06-08
Schwartz (2022) introduces a refined framework for distinguishing between cell death and proliferative arrest in in vitro cancer drug assays, highlighting the limitations of conventional viability metrics. These insights enhance the accuracy of preclinical evaluation for agents like Wee1 kinase inhibitors and support the rational design of combination therapies targeting p53-deficient tumors.
-
Silymarin in Translational Metabolism: Mechanisms, Models, a
2026-06-08
Explore silymarin, a bioactive milk thistle extract, as a sophisticated molecular tool for investigating oxidative stress, metabolic regulation, and antiviral mechanisms. This article provides advanced insights, mechanistic clarity, and protocol guidance for translational research beyond standard workflows.
-
Biomimetic Chromatography for Modeling Pulmonary Drug Permea
2026-06-07
This study rigorously evaluates biomimetic open tubular capillary electrochromatography (OT-CEC) and immobilised artificial membrane chromatography (IAM-LC) coupled with mass spectrometry for modeling lung permeability of pharmaceuticals. The findings highlight the strengths and mechanistic underpinnings of each approach, providing new avenues for high-throughput permeability assessment in drug development.
-
Lipidomics Reveals Ginsenoside F1's Modulation of Hepatic Li
2026-06-06
This study leverages lipidomics to elucidate how ginsenoside F1 counteracts free fatty acid-induced metabolic disturbances in HepG2 cells. By identifying targeted shifts in lipid species and metabolic pathways, the research advances our mechanistic understanding of hepatic lipid dysregulation and suggests new intervention avenues for metabolic disorders.
-
Self-Microemulsifying System Dramatically Boosts Luteolin Up
2026-06-05
The reference study introduces a luteolin-loaded self-microemulsifying drug delivery system (Luteolin-SME) that markedly enhances oral bioavailability by inhibiting P-glycoprotein efflux. This innovation achieved a 29-fold increase in systemic exposure and demonstrated low cytotoxicity, offering a robust approach for improving the pharmacokinetics of poorly absorbed natural compounds.
-
Dual Enzyme-Responsive Zwitterionic Peptide Achieves Cancer
2026-06-05
This study introduces a zwitterionic peptide amphiphile engineered for dual enzyme responsiveness, enabling highly selective lysosomal self-assembly in cancer cells. The approach delivers an exceptional cancer selectivity index and in vivo efficacy, offering new strategies for minimizing off-target toxicity in peptide-based therapeutics.
-
Self-Microemulsifying System Elevates Luteolin Bioavailabili
2026-06-04
This study presents a self-microemulsifying drug delivery system (SME) for luteolin, leveraging P-glycoprotein efflux inhibition to achieve a dramatic increase in oral bioavailability. The findings suggest a robust platform for enhancing the pharmacokinetic performance of bioactive flavonoids, with promising implications for pharmaceutical and nutraceutical development.
-
Advances in Silybin Chemistry: Implications for Milk Thistle
2026-06-04
Křen et al.'s review provides a comprehensive analysis of silybin—the principal flavonolignan in milk thistle extract—detailing its chemical structure, stereochemistry, and the evolution of preparative and derivatization methods. These insights underpin silybin’s role as a versatile reference compound for oxidative stress, hepatocellular carcinoma, and metabolic research, while clarifying limitations in formulation and experimental transferability.
-
High-Content Drug Screening Reveals Src Vulnerabilities in C
2026-06-03
This study applied image-based high-content drug screening to uncover new therapeutic vulnerabilities in conjunctival melanoma cell lines. Notably, Src kinase inhibition—exemplified by compounds such as Tirbanibulin dihydrochloride—emerged as a promising strategy, with implications for precision-targeted therapy development.
-
Merimepodib (VX-497): Transforming Antiviral and Immunology
2026-06-03
Merimepodib (VX-497) empowers researchers to precisely dissect nucleotide metabolism, offering robust, selective IMPDH inhibition for antiviral, cancer, and immunology studies. Its proven specificity and cross-species efficacy make it indispensable for high-impact experimental designs targeting guanine nucleotide biosynthesis.
-
Dopamine Inhibits Osteoclastogenesis via cAMP/PKA/CREB Pathw
2026-06-02
Wang et al. delineate how dopamine suppresses osteoclast differentiation by engaging the cAMP/PKA/CREB signaling axis in bone cells. Their work clarifies a neuroendocrine mechanism of bone remodeling, providing a molecular framework for future research into nervous system regulation of skeletal health.
-
FPH1 (BRD-6125): Advancing Hepatocyte Proliferation for Tran
2026-06-02
This article delivers mechanistic insights and strategic guidance for leveraging FPH1 (BRD-6125) in primary human hepatocyte culture and iPSC-derived hepatocyte workflows. By integrating recent advances in optogenetic gene regulation, we map out a forward-thinking strategy for translational researchers seeking scalable, donor-independent hepatic models and therapeutic platforms. The discussion critically bridges functional proliferation, emerging gene switches, and the evolving landscape of cell-based therapies.
-
Grazoprevir Hydrate (MK-5172): Clinical Pharmacology and Pre
2026-06-01
Explore the advanced clinical pharmacology of Grazoprevir hydrate (MK-5172 hydrate), an oral HCV NS3/4A protease inhibitor with unique efficacy in challenging hepatitis C populations. Learn how its pharmacokinetic profile and real-world outcomes inform best-practice decisions for diverse patient cohorts.
-
(-)-Epigallocatechin gallate (EGCG): Neuroprotection and Ant
2026-06-01
Explore how (-)-Epigallocatechin gallate (EGCG), a major green tea catechin, drives neuroprotection and antioxidant intervention in neurodegenerative disease models. This in-depth article uncovers EGCG’s mechanisms, translational potential, and unique research applications beyond standard apoptosis and antiangiogenic assays.
-
KX2-391 Dihydrochloride: Dual Src & Tubulin Inhibitor Benchm
2026-05-31
KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) is a dual mechanism small molecule that potently inhibits Src kinase and tubulin polymerization, with validated anticancer, antiviral, and neurotoxin-inhibitory activities. The compound demonstrates nanomolar potency in cellular assays, clinical efficacy in actinic keratosis, and a distinctive capacity to block BoNT/A activity in neuronal models.